Galmed Pharmaceuticals (GLMD) Competitors $1.83 -0.50 (-21.46%) Closing price 04:00 PM EasternExtended Trading$1.90 +0.08 (+4.10%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLMD vs. LPTX, IMCC, SNPX, BTAI, NERV, PHIO, BGXX, EQ, ABP, and BCLIShould you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Leap Therapeutics (LPTX), IM Cannabis (IMCC), Synaptogenix (SNPX), BioXcel Therapeutics (BTAI), Minerva Neurosciences (NERV), Phio Pharmaceuticals (PHIO), Bright Green (BGXX), Equillium (EQ), Abpro (ABP), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "pharmaceutical products" industry. Galmed Pharmaceuticals vs. Its Competitors Leap Therapeutics IM Cannabis Synaptogenix BioXcel Therapeutics Minerva Neurosciences Phio Pharmaceuticals Bright Green Equillium Abpro Brainstorm Cell Therapeutics Galmed Pharmaceuticals (NASDAQ:GLMD) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Which has higher valuation & earnings, GLMD or LPTX? Leap Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalmed PharmaceuticalsN/AN/A-$7.52M-$16.66-0.11Leap TherapeuticsN/AN/A-$67.56M-$1.70-0.20 Do analysts prefer GLMD or LPTX? Leap Therapeutics has a consensus target price of $3.38, suggesting a potential upside of 881.10%. Given Leap Therapeutics' higher possible upside, analysts clearly believe Leap Therapeutics is more favorable than Galmed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor GLMD or LPTX? In the previous week, Galmed Pharmaceuticals' average media sentiment score of 1.89 beat Leap Therapeutics' score of 1.87 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Galmed Pharmaceuticals Very Positive Leap Therapeutics Very Positive Is GLMD or LPTX more profitable? Galmed Pharmaceuticals' return on equity of -32.21% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Galmed PharmaceuticalsN/A -32.21% -28.59% Leap Therapeutics N/A -162.15%-120.05% Do institutionals & insiders hold more shares of GLMD or LPTX? 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Comparatively, 7.5% of Leap Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, GLMD or LPTX? Galmed Pharmaceuticals has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.28, meaning that its stock price is 128% less volatile than the S&P 500. SummaryGalmed Pharmaceuticals beats Leap Therapeutics on 8 of the 10 factors compared between the two stocks. Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLMD vs. The Competition Export to ExcelMetricGalmed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.85M$2.46B$5.54B$9.41BDividend YieldN/A1.80%3.75%4.03%P/E Ratio-0.114.4521.0120.09Price / SalesN/A709.89433.8199.01Price / CashN/A164.7736.1658.27Price / Book0.195.008.125.65Net Income-$7.52M$30.99M$3.25B$257.91M7 Day Performance-5.18%1.69%0.97%2.09%1 Month Performance2.81%9.20%7.36%11.13%1 Year Performance-51.04%-1.25%31.31%18.40% Galmed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLMDGalmed Pharmaceuticals1.2597 of 5 stars$1.83-21.5%N/A-39.1%$3.85MN/A-0.1120LPTXLeap Therapeutics2.2572 of 5 stars$0.28-2.6%$3.38+1,089.2%-84.5%$12.07MN/A-0.1740Positive NewsIMCCIM Cannabis0.0853 of 5 stars$3.30+11.5%N/A+44.6%$11.97M$39.44M-5.16340SNPXSynaptogenix0.2484 of 5 stars$8.50+5.2%$14.00+64.7%+107.8%$11.82MN/A-0.844Positive NewsGap UpBTAIBioXcel Therapeutics4.2411 of 5 stars$1.90-1.6%$42.60+2,142.1%-90.5%$11.69M$2.27M-0.1490Positive NewsNERVMinerva Neurosciences4.2419 of 5 stars$1.64-0.6%$5.00+204.9%-40.6%$11.54MN/A2.009PHIOPhio Pharmaceuticals2.6118 of 5 stars$2.55+6.3%$14.00+449.0%-48.5%$11.52MN/A-0.4010BGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002News CoverageGap DownEQEquillium2.5681 of 5 stars$0.32-0.6%$3.00+840.4%-54.6%$11.47M$41.10M-0.8240ABPAbproN/A$0.19-0.6%$4.00+2,040.2%N/A$11.43M$180K0.0015Positive NewsBCLIBrainstorm Cell Therapeutics1.3515 of 5 stars$1.14-1.7%$30.00+2,531.6%-80.2%$11.41MN/A-0.3440News CoverageGap Down Related Companies and Tools Related Companies LPTX Competitors IMCC Competitors SNPX Competitors BTAI Competitors NERV Competitors PHIO Competitors BGXX Competitors EQ Competitors ABP Competitors BCLI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLMD) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.